Key result
Management of hypertrophic cardiomyopathy relies principally on retrospective studies and clinical experience to alleviate symptoms and prevent sudden cardiac death, as no appropriate clinical trials have been performed.
This review provides a comprehensive overview of the clinical presentation, natural history, and current management strategies for hypertrophic cardiomyopathy, emphasizing symptom relief and risk stratification.
HCM management lacks RCT support; leaves open the need for prospective trials to inform guidelines.
Hypertrophic cardiomyopathy (HCM) is characterised by a thickened but non-dilated left ventricle in the absence of another cardiac or systemic condition capable of producing the magnitude of hypertrophy evident. It is the most common familial genetic disease of the heart (1/500 to 1/1000), as well as the most common cause of sudden cardiac death in young people and athletes. Survival rates of patients with HCM have improved from the 1960s onwards. Natural history in patients with HCM might vary from developing severe heart failure or atrial fibrillation, some die suddenly, often at a young age and in the absence of previous symptoms. Because of its heterogeneous clinical course and expression, HCM frequently presents uncertainty and represents a management dilemma to cardiovascular specialists and other practitioners.
No takes yet. Share an insight, caveat, or question.
Siswanto et al. (2009) conducted a review in Hypertrophic cardiomyopathy (HCM). Pharmacological and invasive management strategies was evaluated. Management of hypertrophic cardiomyopathy relies principally on retrospective studies and clinical experience to alleviate symptoms and prevent sudden cardiac death, as no appropriate clinical trials have been performed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: